This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of +6.76% and +1.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems, Inc. (KRMD) Reports Break-Even Earnings for Q2
by Zacks Equity Research
KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of +100.00% and +6.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MDxHealth SA (MDXH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA (MDXH) delivered earnings and revenue surprises of -15.38% and +0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Bears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for P3 Health Partners (PIII), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)
by Zacks Equity Research
The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
P3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -25.60% and 2.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA (MDXH) delivered earnings and revenue surprises of -46.15% and 0.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of -15.49% and 6.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 62.50% and 4.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
P3 Health Partners (PIII) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
P3 Health Partners (PIII) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -88.24% and 3.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 10.13% and 3.24%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
P3 Health Partners (PIII) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
P3 Health Partners (PIII) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 4.17% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
P3 Health Partners Inc. (PIII) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -933.33% and 1.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 25% and 1.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Moves 13.9% Higher: Will This Strength Last?
by Zacks Equity Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
P3 Health Partners (PIII) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
P3 Health Partners (PIII) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
P3 Health Partners (PIII) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, P3 Health Partners (PIII) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -87.50% and 4.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Privia Health (PRVA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will P3 Health Partners Inc. (PIII) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
by Debanjana Dey
Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.
P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info Systems Stocks to Buy as Industry Rebounds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.